Microcirculation and hemostasis in inflammatory processes;Mikrozirkulation und hamostase bei entzundlichen prozessen modulation durch den einsatz physiologischer protease-inhibitoren als therapeutischer ansatz

Medizinische Klinik

Volumn 92, Issue 7, 1997, Pages 426-431

  Leithäuser, Boris ^a,b   Matthias, F Reinhard ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b Medizinische Klinik II   (Germany)

Author keywords

Antithrombin III; C1 Inhibitor; Hemostatis; Inflammation; Microcirculation; Sepsis

Indexed keywords

ANTITHROMBIN III; COMPLEMENT COMPONENT C1S INHIBITOR; PROTEINASE INHIBITOR;

ADJUVANT THERAPY; BLOOD VESSEL WALL; COMPLEMENT SYSTEM; DRUG MECHANISM; HEMOSTASIS; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; INFLAMMATION; INTENSIVE CARE; MICROCIRCULATION; REVIEW; SEPSIS; VASCULAR ENDOTHELIUM; DRUG EFFECT; PATHOPHYSIOLOGY; PHYSIOLOGY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ANTITHROMBIN III; COMPLEMENT C1 INACTIVATOR PROTEINS; ENDOTHELIUM, VASCULAR; HEMOSTASIS; HUMANS; MICROCIRCULATION; PROTEASE INHIBITORS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0030738120     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03042575     Document Type: Review

References (40)

1. American college of chest physicians/Society of critical care medicine consensus conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit. Care Med. 20 (1992), 864-874.
2. Bengtson, A., H. Redl, M. Heideman, G. Schlag: Complement in septic shock. In: Neugebauer, E. A., J. W. Holaday (eds.). Handbook of mediaton in septic shock. Boca Raton, Ann Arbor CRC Press, London-Tokyo 1993, p. 231-257.
3. Bevilacqua, M. P., M. A. Gimbrone: Inducible endothelial functions in inflammation and coagulation Semin. Thrombos. Hemostas. 13 (1987), 425-433.
4. Blauhut,B, H. Kramar, H. Vinazzer, H. Bergmann: Substitution of antithrombin III in shock and DIC: A randomized study. Thrombos. Res. 39 (1985), 81-89.
5. Buerke, M., T. Murohara, A. M. Lefer: Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion Circulation 91 (1995), 393-402.
6. Cohen, L.: Guidelines for the use of innovative therapies in sepsis. Crit. Care Clin. 21 (1993), 476-477.
7. Davies, M G., P. O. Hagen: The vascular endothelium. A new horizon. Ann Surg. 218 (1993), 593-609.
8. DeLa Cadena, R. A., Y. T. Wachtfogel, R. W. Colman: Contact activation pathway: inflammation and coagulation. In: Colman, R. W , J. Hirsh, V.J. Marder, E. W. Salzman (eds.): Hemostasis and thrombosis: basic principles and clinical practice. 3rd ed. Lippincott Company, Philadelphia 1994, p. 219-240.
9. Dickneite, G., E P Paques: Reduction of mortality with antithrombin III in septicemic rats: a study of klebsiella pneumoniae induced sepsis. Thrombos and Haemostas. 69 (1993), 98-102.
10. Eidelman, L. A., R., Pizov, C. L. Sprung: New therapeutic approaches in sepsis: a critical review. Intens. Care Med. 21 (1995), S269-S272
11. Eisele, B., U. Delvos: From localized angioedema to generalized capillary leak syndrome. In: Reinhart, K., K. Eyrich, C. Sprung (Hrsg.): Update in intensive care and emergency medicine. Sepsis- Current perspectives in pathophysiology and therapy. 18th ed. Springer, Berlin - Heidelberg-New York 1994, p. 501-527.
12. Esmon, C. T., F. B. Taylor, T. R. Snow: Inflammation and coagulation. Linked process potentially regulated through a common pathway by protein C. Thrombos. and Haemostas, 66 (1991), 160-165.
13. Fourrier, F., C. Chopin, J. Goudemand, et al.: Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C and protein S deficiencies. Chest 101 (1992), 816-823.
14. Fourrier, F., C. Chopin, J. J. Huart, I. Runge, C. Caron, J. Goudemand: Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 104 (1993), 882-888.
15. Fourrier, F., M. Jourdain, A. Tournois, C. Caron, J. Goudemand, C Chopin: Coagulation inhibitor substitution during sepsis. Intens. Care Med, 21 (1995), S254-S268.
16. Fourrier, F., P. Lestavel, C. Chopin, et al.: Meningococcemia and purpura fulminans in adults: acute deficiencies of protein C and S and early treatment with antithrombin III concentrates. Intens. Care Med. 16 (1990), 121-124.
17. Glusa, E.: Vascular effects of thrombin. Semin. Thrombos. Hemostas. 18 (1992), 296-304.
18. Hack, C. E , A. C. Ogilvie, B. Eisele, A. J M Eerenberg, J. Wagstaft L. G. Thys: C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high dose interleukin 2 therapy. Intens. Care Med. 19 (1993), S19-S28.
19. Harris, A. G., T. C. Skalak: Effects of leukocyte activation on capillary hemodynamics in skeletal muscle. Amer. J. Physiol. 264 (1993), H909-H916.
20. Haupt, H., N Heimburger, T. Kranz, H. G. Schwick: Ein Beitrag zur Isolierung und Charakterisierung des C1-Inaktivators aus Humanplasma. Europ. J. Biochem. 17 (1970), 254-261.
21. Horie, S., H. Ishii, M. Kazama: Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells. Thrombos, Res. 59 (1990), 895-904.
22. Lamy, M., G. Deby-Dupont: Is sepsis a mediator-inhibitor mismatch? Intens. Care Med. 21 (1995), S250-S257
23. Lamy, M., L. G. Thijs, B. Eisele, H. O. Keinecke, H. P. Schuster, F. R. Matthias, W. Oettinger, U. Hartenauer, F. Fourrier, U. Delvos: Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial. 9th European Congress on Intensive Care Medicine. 1996; Glasgow, UK. In: Intens. Care Med, 22, Suppl. 3 (1996), 342.
24. Leithauser, B., F. R. Matthias, U. Nicolai, R. Voss: Hemostatic abnormalities and the severity of illness in patients at the onset of clinically defined sepsis. Possible indication of the degree of endothelial cell activation? Intens. Care Med. 22 (1996), 631-636.
25. Levi, M., H. ten Cate, T. van der Poll, S. J. H. van Deventer. Pathogenesis of disseminated intravascular coagulation in sepsis. J. Amer. med. Ass. 270 (1993), 975-979.
26. Lucchesi, B. R.: Complement, neutrophils and free radicals: mediators of reperfusion injury. Drug Res. 44 (1994), 420-432.
27. Nuijens, J H., C. C. M. Huijbregts, A. J. M. Eerenberg-Belmer et al.: Quantification of plasma factor XIIa-C1-inhibitor and kallikrein-C1-inhibitor complexes in sepsis. Blood 72 (1988), 1841-1848.
28. Nürnberger, W., I. Michelmann, K. Petrik et al.: Activity of C1 esterase inhibitor in patients with vascular leak syndrome after bone marrow transplantation. Ann Hematol 67 (1993), 17-21.
29. Okajima, K., H. Imamura, S. Koga, M. Inoue, K. Takatsuki, N. Aoki: Treatment of patients with disseminated intravascular coagulation by protein C. Amer. J. Hematol. 33 (1990), 277-278.
30. Pemberton, M., G. Anderson, V. Vetvicka, D E Justus, G. D. Ross: Microvascular effects of complement blockade with soluble recombinant CR1 in ischemia/reperfusion injury of skeletal muscle. J. Immunol. 150 (1993), 5104-5113.
31. Pober, J. S., R. S. Cotran: The role of endothelial cells in inflammation. Transplantation 50 (1990), 537-544.
32. Rowland, F. N., M. J. Donovan, P. T. Picciano, G. D. Wilner, D. L. Kreutzer: Fibrin-mediated vascular injury. Amer. J. Pathol. 117 (1984), 418-428.
33. Schapira, M., A. de Agostini, J. Schifferli, R. W. Colman: Biochemistry and pathophysiology of human Cl inhibitor, current issues, Complement 2 (1985), 111-126.
34. Seitz, R., M Wolf, R. Egbring, K. Havemann: The disturbance of hemostasis in septic shock: role of neutrophil elastase and thrombin, effects of antithrombin III and plasma substitution. Europ. J. Haematol. 43 (1989), 22-28.
35. Sibbald, W. J., J. L. Vincent: Round table conference on clinical trials for the treatment of sepsis. Crit. Care Med. 23 (1995), 394-399.
36. Taylor, F. B , A. Chang, C. T. Esmon, A D'Angelo, S. Vigano-D'Angelo, K. E. Blick: Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon J. clin Invest. 79 (1987), 918-925.
37. Taylor, F. B., T. E. Emerson, R. E. Jordan, A Chang, K. E Blick. Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. Circulat. Shock. 26 (1988), 227-235.
38. Thijs, L. G., J P. de Boer, M. C. M. de Groot, C. E. Hack: Coagulation disorders in septic shock. Intens. Care Med 19 (1993), S8-S15.
39. Uchiba, M. K. Okajima, K Murakami, H. Okabe, K. Takatsuki: Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Amer, J. Physiol. 270 (1996), L921-L930
40. Voss, R., F. R Matthias, G, Borkowski, D. Reitz: Activtion and inhibition of fibrinolysis in septic patients in an internal intensive care unit. Brit. J. Haematol. 75 (1990), 99-105.